Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01988090 · ClinicalTrials.gov registry record · Phase 2

High Dose Vitamin D vs Standard Dose Vitamin D Study

A Phase 2 study, sponsored by Mothaffar Rimawi.

Terminated
Registry status
Phase 2
Development phase
93
Enrollment target

NCT01988090: Clinical Trial Phase 2 study, sponsored by Mothaffar Rimawi.

NCT01988090 is a Phase 2 study that was terminated before completion, run by Mothaffar Rimawi. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01988090, a Phase 2 study, was terminated before completion, sponsored by Mothaffar Rimawi.

TERMINATED
Registry status
Phase 2
Development phase
93 participants
Enrollment target

Study Summary

This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. The investigators hope to learn if taking a higher dose of Vitamin D is a good way to prevent aromatase inhibitor arthralgia (AIA).

Primary Outcome

Aromatase Inhibitor Arthralgia (AIA) was assessed by a questionnaire that describe the level of pain experienced by the participant. The questionnaire asks 20 questions scored 0-3 in 8 categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. An average composite score on the HAQ-II was calculated. The visual analog scale is the other major component of the HAQ-II, which we ask patients to mark where their pain lies on a horizontal line and we conv

Interventions

  • DRUG 800 IU Vitamin D Supplement
  • DRUG 50,000 IU Vitamin D supplement

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2013-12
Est. Completion 2018-12-10
Phase Phase 2
Mothaffar Rimawi

6 total trials

Why NCT01988090 stopped before completion

NCT01988090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).

The record links to 0 conditions, and to 2 interventions - of which 800 IU Vitamin D Supplement is the first listed.

NCT01988090 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01988090 about?

NCT01988090 is a clinical study titled "High Dose Vitamin D vs Standard Dose Vitamin D Study". This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. The investigators hope to lear...

What is the current status of trial NCT01988090?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2013-12. Estimated completion is 2018-12-10.

What interventions are being tested in trial NCT01988090?

The interventions under investigation include: 800 IU Vitamin D Supplement (DRUG), 50,000 IU Vitamin D supplement (DRUG).

Who is sponsoring clinical trial NCT01988090?

This trial is sponsored by Mothaffar Rimawi, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01988090's enrollment target sits among peer trials

93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01988090, the US trial registry maintained by the National Library of Medicine. NCT01988090 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.